UF researcher receives grant for stem cell transplant study

By Ian Bennett

Jordan Milner, M.D., a clinical assistant professor in the division of hematology & oncology in the department of pediatrics in the University of Florida College of Medicine, has been awarded a $125,000 grant from the Live Like Bella® Pediatric Cancer Research Initiative to study the use of alpha/beta T-cell and B-cell depletion in allogeneic stem cell transplantation in malignant diseases. 

Jordan Milner, M.D.

“We are thrilled to bring this technology to the University of Florida and provide our patients with state-of-the-art techniques in hopes to decrease allogeneic transplant related morbidities,” said Milner, a member of the Cancer Center’s Cancer Therapeutics & Host Response research program.

Allogeneic stem cell transplantation, or alloSCT, is a promising treatment option for pediatric patients with malignant diseases, but it is associated with a risk of transplant-related complications such as graft-versus-host disease. Alpha/beta CD3+ T-cell and CD19+ B-cell depletion is a technique to reduce the risk of graft-versus-host disease and post-transplant lymphoproliferative disorder. However, its use in pediatric alloSCT for malignant diseases has not been well studied. 

Milner aims to evaluate the use of alpha/beta CD3+ T-cell and CD19+ B-cell depletion in pediatric alloSCT recipients. The Milner lab will submit for approval a single institution, prospective, phase 2 trial to test the hypothesis that pediatric patients who undergo alloSCT using alpha/beta CD3+ T-cell and CD19+ B-cell depletion will have a lower incidence of graft-versus-host disease than matched sibling donor alloSCT patients while maintaining a comparable overall survival. The technique could also lower the risk of graft-versus-host disease, engraftment failure and delayed immune reconstitution, without increasing the risk of infection or post-transplant lymphoproliferative disorder. 

All patients will be monitored for myeloid and platelet engraftment, development of graft-versus-host disease, engraftment failure, infections and development of post-transplant lymphoproliferative disorder. 

NCI Cancer Center badge